On May 22, 2024 I-Mab (NASDAQ: IMAB), a U.S.-based global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, reported that management will present at the Jefferies Global Healthcare Conference on June 5, 2024 (Press release, I-Mab Biopharma, MAY 22, 2024, View Source [SID1234643552]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference

Presentation Time

Wednesday, June 5 at 9:30 a.m. EST

Presenters

Raj Kannan, CEO; Louie Naumovski, Interim CMO

Webcast link

Here

Meetings

One-on-one and small group meetings: June 5, 2024

Management
Participants

Raj Kannan, CEO

Joe Skelton, CFO

Louie Naumovski, Interim CMO

Tyler Ehler, Senior Director, Investor Relations

The webcast will also be available under "Event Calendar" on I-Mab’s IR website
at View Source

For more information, please contact your Jefferies representative.

On May 22, 2024 GV20 Therapeutics, a clinical-stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, reported that it will present at the Jefferies Global Healthcare Conference Private Biotech Day, taking place June 4th, 2024, in New York (Press release, GV20 Therapeutics, MAY 22, 2024, View Source [SID1234643550]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company management will be conducting one-on-one meetings with investors at the conference.

On May 22, 2024 NeoPhore Limited, a small molecule neoantigen immuno-oncology company, reported that Bristol Myers Squibb (NYSE: BMY) has joined its oversubscribed Series B extension round (Press release, NeoPhore, MAY 22, 2024, View Source [SID1234643549]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The additional investment from Bristol Myers Squibb will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (‘MMR’) pathway in cancer, as well as further progress its pre-clinical studies and deliver a candidate drug in 2025.

NeoPhore is focused on building a pipeline of small molecule drugs targeting novel proteins across the MMR pathway to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. Its first-in-class MMR inhibitors induce neoantigen expression and increase immunogenicity in solid tumours that become exquisitely sensitive to immunotherapy.

Dr Matthew Baker, Chief Executive Officer of NeoPhore, said: "We are thrilled to have Bristol Myers Squibb, an innovator in the immuno-oncology space, join our oversubscribed Series B extension round. The funding strengthens NeoPhore’s position and enables us to complete the necessary pre-clinical studies to deliver a candidate drug for our lead PMS2 program in 2025."

Dr Robert James, Chairman of NeoPhore, said: "The addition of Bristol Myers Squibb to the Series B extension supports NeoPhore’s novel approach to targeting the MMR pathway with small molecule inhibitors to treat cancer. Building on NeoPhore’s successes in 2023, we hope to see a year of progress for the Company’s pre-clinical programs".

On May 22, 2024 Accuray Incorporated (NASDAQ: ARAY) reported its participation in the Jefferies Global Healthcare Conference 2024 (Press release, Accuray, MAY 22, 2024, View Source [SID1234643548]). The management team is scheduled to participate in a fireside chat on Wednesday, June 5, 2024 at 7:30am EDT/4:30am PDT

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the call will also be available from the Investor Relations section of the company’s website at investors.accuray.com. A webcast replay can be accessed on the website and will remain available for 90 days.

On May 22, 2024 Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, reported that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology (Press release, Nona Biosciences, MAY 22, 2024, View Source [SID1234643547]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Under the terms of the agreement, Nona Biosciences shall receive US$19 million upon completion of the transaction. Nona is eligible to receive an additional US$10 million in potential near-term milestone payments and up to US$575 million upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales. In addition, Nona is eligible to receive payments for the option programs should AstraZeneca exercise these options.

"We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumor targeted therapies, to maximize the potential of our novel antibodies," said Jingsong Wang, M.D., Ph.D., Chairman of Nona Biosciences. "This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients."

Puja Sapra, Senior Vice President, Tumour Targeted Delivery, Oncology R&D, AstraZeneca, said: "The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona’s innovative biologics discovery engine into novel tumor targeted therapies using AstraZeneca’s industry-leading capabilities."